Harmony Biosciences Holdings, Inc. — Form 8-K Summary
Reporting date: August 31, 2020. This 8-K reports an unregistered issuance of common stock following the conversion of all outstanding preferred stock in connection with the company’s initial public offering, and provides an FDA regulatory update for WAKIX. It does not provide a new income statement, balance sheet, cash flow statement, or operating-period financial results.
Capitalization and Transaction Details
- Previously outstanding Series A, Series B, and Series C preferred stock converted into common stock.
- Preferred stockholders received an aggregate of 42,926,630 shares of unregistered common stock, including shares issued in payment of cumulative accrued dividends.
- Total common shares outstanding after the conversion were 56,883,640 shares.
- Fractional shares were paid in cash.
- Substantially all common shares issued to former preferred stockholders are subject to a lock-up expiring 180 days after the August 18, 2020 IPO pricing date.
- The preferred stock issuances were made in reliance on Securities Act Section 4(a)(2) and Regulation D exemptions.
- The disclosed preferred stock figures reflect the company’s 1-for-8.215 reverse stock split effected August 11, 2020.
Historical Preferred Stock Financings
| Series | Shares Issued | Price per Share | Aggregate Consideration |
|---|---|---|---|
| Series A | 34,692,635 | $8.22 | Approximately $285.0 million |
| Series B | 973,828 | $10.27 | Approximately $10.0 million |
| Series C | 3,105,320 | $16.10 | Approximately $50.0 million |
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity measures, or financial guidance. The reported share conversion and dividend settlement are capitalization events rather than operating-period financial results.
Material Changes and Outlook
- The principal capitalization change was the conversion of all outstanding preferred stock into common stock and the related increase in common shares outstanding.
- The FDA acknowledged that Harmony’s complete response resubmission for the adult cataplexy indication of WAKIX was a complete Class 1 response to the FDA’s August 14, 2019 action letter.
- The FDA user fee goal date, or decision date, was set for October 13, 2020.
- The FDA decision remained a material regulatory contingency; the filing does not state the eventual outcome.
Important Facts for Investors to Verify
- Confirm the final number of common shares outstanding after the preferred-stock conversion and accrued-dividend issuance.
- Review the IPO prospectus and capitalization tables for the effect of the reverse stock split, conversion terms, and lock-up provisions.
- Verify the October 13, 2020 FDA decision date and the eventual regulatory outcome for the adult cataplexy indication of WAKIX.
- Review subsequent filings for financial performance, cash resources, debt, dilution, and any sales of shares released from lock-up restrictions.